Reference10 · 02 · 20266 min read

Coring: When A Stopper Sheds Into The Vial

Coring is the removal of a piece of elastomer from a vial stopper when the closure is pierced, leaving a visible fragment inside the container. It is not a random event: fragmentation rate is a function of the rubber formulation, the closure geometry, the piercing angle and how many times the same site has been penetrated. Pharmacopoeial fragmentation testing exists to put a number on it.

A vial closure is a moulded elastomer disc held against the glass sealing surface by an aluminium crimp. Piercing it works because the rubber is elastic: the material parts around the advancing point, then closes behind it when the point withdraws. Coring is the case where the material does not part but is cut out, so a fragment separates and falls into the container.

The fragment is usually small, on the order of tens to a few hundred micrometres across, and it is the same halobutyl rubber and filler mix as the rest of the closure. It is a visible particulate in the container, and a container with visible particulate has failed a basic inspection criterion regardless of what the particulate is made of.

The property being described belongs to the closure, not to the contents. Two vials of identical material can have quite different fragmentation behaviour purely because the stoppers came from different formulations or different mould tooling.

The material variables that set fragmentation rate

Closure elastomers for parenteral containers are predominantly bromobutyl or chlorobutyl rubber, compounded with mineral fillers, a vulcanisation system and often a fluoropolymer laminate on the product-contact face. Each of those choices moves the fragmentation number.

  • Hardness, reported in degrees Shore A. Closures for parenteral containers commonly fall between about 40 and 55 Shore A. Harder compounds resist deformation and are more prone to being cut rather than displaced.
  • Cross-link density from the vulcanisation system. Lightly vulcanised rubber tears; heavily vulcanised rubber cuts.
  • Filler loading. Mineral filler raises modulus and lowers elongation at break, and low elongation at break is the mechanical property most directly associated with fragment separation.
  • Septum thickness at the piercing site, typically 2 mm to 4 mm in the target area of a moulded closure. Thicker septa require a longer cutting path and shed more readily.
  • Surface finish. Silicone applied to the closure lowers the friction of penetration, and a fluoropolymer laminate changes the mechanics of the contact face.
VariableChangeEffect on fragmentation
Hardness (Shore A)HigherIncreases
Elongation at breakLowerIncreases
Septum thickness at piercing siteThickerIncreases
Penetration angle from perpendicularLargerIncreases
Piercing point diameterLargerIncreases
Silicone surface finishPresentDecreases
Penetrations at the same siteMoreIncreases
Variables affecting fragmentation, and the direction of their effect, as characterised in elastomeric closure functional testing per ISO 8871-5.

How fragmentation is counted

The pharmacopoeial fragmentation test is a counting exercise rather than a pass on appearance. A defined set of closures is pierced a defined number of times under specified conditions using a point of specified gauge and bevel, the liquid contents are filtered through a membrane, and the fragments retained on the membrane are counted visually. The commonly applied acceptance criterion for closures intended for aqueous parenteral containers is no more than five fragments across one hundred penetrations, with a retest allowance where the count sits marginally above.

Two features of that method are worth naming. The first is that the criterion is a batch statistic, not a per-vial guarantee: a compliant closure lot can still shed on an individual piercing. The second is that the test fixes the geometry, so the number it produces is only transferable to real conditions that match that geometry. Change the point diameter or the angle and the measured rate no longer applies.

The companion functional properties measured on the same closures are penetration force, in newtons, and self-sealing capacity, both defined in ISO 8871-5 and in the corresponding European Pharmacopoeia method. Penetration force and fragmentation trade against each other: compounds engineered for very low penetration force tend to be softer and shed less, but soft compounds have other trade-offs in seal retention and coring is only one of the criteria a closure is selected against.

The failure mode: repeated penetration of one site

The single most reliable way to produce a fragment is to pierce the same point in the septum more than once. The first penetration displaces material and leaves a channel that does not fully recover; elastic recovery in a butyl compound is high but not complete. A second point entering that weakened channel meets partly severed material rather than intact rubber, and the fragmentation rate for a given closure climbs steeply with the penetration count at one site.

It shows up as one or more discrete grey or black specks resting on the cake, or suspended in solution and slow to settle because the fragment's density is close to water. Against a white lyophilized cake the specks are visible without magnification; in solution they are easier to see with the container held against a black background and lit from the side, which is the arrangement used in pharmacopoeial visible particulate inspection.

Why sedimented fragments are easy to miss

Fragment detection is a genuinely low-sensitivity operation. Visible particulate inspection by unaided eye is generally reliable down to roughly 100 µm to 150 µm under good lighting, and much less so below that. A coring fragment can sit near or below that threshold, in which case it is present, real, and not observable by inspection at all.

This is why the closure specification matters more than the inspection. Fragmentation is controlled at the point the closure is selected and qualified, not at the point someone looks into a vial. The look is a last check with a coarse detection limit, not a control.

Where closure data sit in the published record

Fragmentation, penetration force and self-sealing figures are not among the specifications Aurum publishes. Where that testing exists it was performed by the closure manufacturer on a closure lot, against the geometry the standard fixes, and it does not appear in the published record for a vial of material.

Nor is particulate matter testing among the published specifications, and no claim is made that any container is free of visible or sub-visible particulate. Sterility, endotoxin and pyrogen testing are not performed and not claimed, and fragmentation testing speaks to none of them. What is published is purity by reverse-phase HPLC and identity by mass spectrometry, both statements about the peptide, neither a statement about the container it sits in.

Common questions

Is coring the same thing as a closure failing its seal?

No. Coring is loss of material from the septum. Seal integrity is measured separately, by container closure integrity methods such as those described in USP <1207>, and a closure can shed a fragment while still sealing, or seal poorly without shedding anything.

Does the fragment dissolve?

No. Vulcanised butyl rubber with mineral filler is insoluble in water and in the alcohols and buffers typical of peptide work. A fragment stays a fragment.

Do coated stoppers core less?

A fluoropolymer laminate changes the contact face and can change the mechanics at the piercing site, but it is applied for extractables control rather than for fragmentation, and the fragmentation number still has to be measured on the finished closure.

Why is the piercing angle so influential?

A point entering at an angle presents its cutting edge to the rubber over a longer path and with a sideways component, which slices rather than parts the material. Perpendicular entry gives the shortest path and the most symmetric deformation.

Is a black speck always a stopper fragment?

Not necessarily. Other dark particulate sources exist, including carbonised material from glass forming and foreign matter introduced during filling. Identification requires analysis, commonly infrared microspectroscopy, not appearance.

References

  1. 01International Organization for Standardization ISO 8871-5: Elastomeric parts for parenterals and for devices for pharmaceutical use, Part 5: Functional requirements and testing. ISO, 2016.
  2. 02European Directorate for the Quality of Medicines European Pharmacopoeia 3.2.9 Rubber Closures for Containers for Aqueous Parenteral Preparations. Ph. Eur..
  3. 03United States Pharmacopeia General Chapter <659> Packaging and Storage Requirements. USP–NF.
  4. 04United States Pharmacopeia General Chapter <1207> Package Integrity Evaluation for Sterile Products. USP–NF.
  5. 05International Organization for Standardization ISO 8871-1: Elastomeric parts for parenterals and for devices for pharmaceutical use, Part 1: Extractables in aqueous autoclavates. ISO, 2003.
  6. 06European Directorate for the Quality of Medicines European Pharmacopoeia 2.9.20 Particulate Contamination: Visible Particles. Ph. Eur..

Every citation links out to the paper on PubMed. Identifiers are omitted deliberately rather than reproduced from memory, so where we do not hold a verified PMID or DOI the link is a PubMed search for that exact title — it resolves to the paper without anything being invented.

FOR RESEARCH USE ONLY · NOT INTENDED FOR HUMAN CONSUMPTION. This article describes compounds and the research literature in which they appear. Nothing here is a recommendation, protocol, or statement of effect.

More from the journal

Keep reading.